Document is current
Any future updates will be listed below
-
Authors
de Barrios, Oriol
Ocón-Gabarró, Ingrid
Gusi-Vives, Mar
Collazo, Olga
Meler, Ainara
Romecín, Paola A.
Martínez-Moreno, Alba
Tejedor, Juan Ramón
Fraga, Mario F.
Schneider, Pauline
Bardini, Michela
Cazzaniga, Giovanni
Marschalek, Rolf
Stam, Ronald W.
Bueno, Clara
Menéndez, Pablo
Parra, Maribel
-
Funding
Funding for this research was provided by:
Fundación Científica Asociación Española Contra el Cáncer (POSTD20024DEBA)
Ministerio de Ciencia e Innovación (RYC2021-031197-I, MICINN, EUR2019-103835)
José Carreras Leukämie-Stiftung (DJCLS/07R/2022, DJCLS/07R/2022, DJCLS/07R/2022)
Agencia Estatal de Investigación (PRE2018-083183)
Fight Kids Cancer Funding Programme (Cure2MLL, Cure2MLL, Cure2MLL)
Instituto de Salud Carlos III (PI20/00822, PI21/01451)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 9 July 2025
First Online: 28 July 2025
Declarations
:
: The experimental work proposed in this study involving primary human samples has been approved by the IRB board at Germans Trias i Pujol hospital, at Can Ruti Campus in Badalona (approval code: PI21/01451). Patient samples from KMT2A germline and t(4;11) pro-B-ALL were obtained with the authorization from patients’ legal representatives. All animal procedures involved are approved by the Animal Research Ethics Committee of CMCiB-IGTP facility (20–004-JRU-P5) and the Animal Research Commission from the Government of Catalonia (CEA/10473_MR2/P5).
: All contributing authors have agreed to publish this manuscript.
: PM is cofounder of OneChain Immunotherapeutics, a spin-off company focused on CAR-T cells with no connection with the present work. The rest of the authors declare no competing interests.
